Literature DB >> 23229481

In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus.

Vincent H Tam1, Kai-Tai Chang, Zhen Yang, Joseph Newman, Ming Hu.   

Abstract

AZD5206 is a novel antimicrobial agent with potent in vitro activity against Staphylococcus aureus. We evaluated the in vitro pharmacodynamics of AZD5206 against a standard wild-type methicillin-susceptible strain (ATCC 29213) and a clinical strain of methicillin-resistant S. aureus (SA62). Overall, bacterial killing against a low baseline inoculum was more remarkable. Low dosing exposures and/or high baseline inoculum resulted in early reduction in bacterial burden, followed by regrowth and selective amplification of the resistant population.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23229481      PMCID： PMC3553694          DOI： 10.1128/AAC.01208-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  The inoculum effect: fact or artifact?

Authors:  William A Craig; Sujata M Bhavnani; Paul G Ambrose
Journal:  Diagn Microbiol Infect Dis       Date:  2004-12       Impact factor: 2.803

Review 2.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

3.  Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.

Authors:  V H Tam; A Louie; T R Fritsche; M Deziel; W Liu; D L Brown; L Deshpande; R Leary; R N Jones; G L Drusano
Journal:  J Infect Dis       Date:  2007-05-02       Impact factor: 5.226

4.  Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Samer Kabbara; Giao Vo; Amy N Schilling; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 5.  Optimizing dosage to prevent emergence of resistance - lessons from in vitro models.

Authors:  Renu Singh; Vincent H Tam
Journal:  Curr Opin Pharmacol       Date:  2011-08-23       Impact factor: 5.547

6.  Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.

Authors:  Shingo Mizunaga; Tomoko Kamiyama; Yoshiko Fukuda; Masahiro Takahata; Junichi Mitsuyama
Journal:  J Antimicrob Chemother       Date:  2005-05-12       Impact factor: 5.790

7.  Impact of recA on levofloxacin exposure-related resistance development.

Authors:  Renu Singh; Kimberly R Ledesma; Kai-Tai Chang; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

8.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079
  8 in total
  4 in total

1.  NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Authors:  Thomas J Dougherty; Asha Nayar; Joseph V Newman; Sussie Hopkins; Gregory G Stone; Michele Johnstone; Adam B Shapiro; Mark Cronin; Folkert Reck; David E Ehmann
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.

Authors:  Soon-Ee Cheah; Jian Li; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.

Authors:  Adam B Shapiro; Joseph Newman; Kosalaram Goteti; Marie-Eve Beaudoin; Rane Harrison; Sussie Hopkins; Nikunj Agrawal; Olga Rivin
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

4.  In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.

Authors:  A J Lepak; P Seiler; J P Surivet; D Ritz; C Kohl; D R Andes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.